View Post

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

In Clinical Studies News by Barbara Jacoby

By: Rachel Narozniak, MA From: For the first time in the therapeutic landscape of metastatic triple-negative breast cancer (mTNBC), treatment options now include an antibody-drug conjugate (ADC). The aggressive subtype is associated with poor prognoses. On April 22, 2020, the FDA granted an accelerated approval to sacituzumab govitecan-hziy (Trodelvy) for adults with mTNBC who have received at least 2 …